Teva Forecasts 2024 Adjusted EPS Of $2.40-$2.50 Versus Prior Guidance Of $2.30-$2.50 And Consensus Of $2.45
Benzinga
Nov 06, 2024
Outlook for 2024 Non-GAAP Results
$ billions, except EPS or as noted
November 2024 Outlook
July 2024 Outlook
February 2024 Outlook
Revenues*
$16.1 - $16.5
$16.0 - $16.4
$15.7 - $16.3
AUSTEDO ($m)*
~1,600
~1,600
~1,500
AJOVY ($m)*
~500
~500
~500
UZEDY ($m)*
~100
~80
~80
COPAXONE ($m)*
~500
~450
~400
Operating Income
4.2 - 4.5
4.1 - 4.5
4.0 - 4.5
Adjusted EBITDA
4.7 - 5.0
4.6 - 5.0
4.5 - 5.0
Finance Expenses ($m)
~1,000
~1,000
~1,000
Tax Rate
14% - 17%
14% - 17%
14% - 17%
Diluted EPS ($)
2.40 - 2.50
2.30 - 2.50
2.20 - 2.50
Free Cash Flow**
1.7 - 2.0
1.7 - 2.0
1.7 - 2.0
CAPEX*
~0.5
~0.5
~0.5
Foreign Exchange
Volatile swings in FX can negatively impact revenue and income
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.